Yiheng Capital Management L.P. Sells 10,000 Shares of Kymera Therapeutics, Inc. $KYMR

Yiheng Capital Management L.P. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 13.6% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 63,440 shares of the company’s stock after selling 10,000 shares during the period. Kymera Therapeutics accounts for approximately 2.5% of Yiheng Capital Management L.P.’s holdings, making the stock its 11th biggest position. Yiheng Capital Management L.P. owned about 0.08% of Kymera Therapeutics worth $7,275,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of KYMR. Smartleaf Asset Management LLC grew its position in shares of Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC boosted its stake in Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the period. Osaic Holdings Inc. grew its holdings in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Kymera Therapeutics by 27.5% in the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock worth $52,000 after buying an additional 98 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the fourth quarter worth $63,000.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 50,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total value of $5,950,000.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $79,321,592. The trade was a 6.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the completion of the transaction, the director owned 240,123 shares in the company, valued at $25,573,099.50. This represents a 86.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,587,629 shares of company stock worth $386,183,782 over the last ninety days. 15.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently weighed in on KYMR shares. Wells Fargo & Company raised their target price on shares of Kymera Therapeutics from $116.00 to $151.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank Of Canada lowered Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price objective for the company from $106.00 to $115.00 in a research report on Monday, July 13th. Morgan Stanley reaffirmed an “overweight” rating and issued a $135.00 target price on shares of Kymera Therapeutics in a report on Thursday, August 6th. B. Riley Financial boosted their target price on Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Loop Capital set a $97.00 price objective on Kymera Therapeutics in a research note on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $127.17.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $118.15 on Monday. The company’s fifty day simple moving average is $112.78 and its 200-day simple moving average is $93.71. The company has a market cap of $9.82 billion, a P/E ratio of -36.47 and a beta of 1.95. Kymera Therapeutics, Inc. has a twelve month low of $39.84 and a twelve month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last announced its earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The business had revenue of $65.00 million during the quarter, compared to analyst estimates of $32.78 million. During the same quarter in the previous year, the business earned ($0.95) earnings per share. The company’s revenue for the quarter was up 465.2% compared to the same quarter last year. Analysts predict that Kymera Therapeutics, Inc. will post -3.78 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.